Recently, Tucidinostat (also known as Chidamide), a selective HDAC1, 2, 3, and 10 inhibitor, has been trialed in combination with Exemestane in advanced hormone receptor-positive (HR+) breast cancer patients to combat acquired resistance [71,75]. This evidence concerns the gene HDAC1 and breast carcinoma.